Barbara Gayle Duncan - Feb 3, 2023 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role: Director
Signature: /s/ James R. Oehler, Attorney-in-Fact
Stock symbol: HALO
Transactions as of: Feb 3, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/7/2023, 03:06 PM
Previous filing: Jul 1, 2022
Next filing: Feb 27, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HALO	Common Stock	Award	$0	+1.19K		$0.00	1.19K	Feb 3, 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

Content

Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.